An interventional study of Keep It Up! 3.0 in HIV/AIDS, Gonorrhea and Chlamydia, sponsored by Northwestern University. Completed at 1 site in United States. Open to male participants aged 18 Years to 34 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Northwestern University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States — 112 open to participants now, 154 under way, 9 of them phase 3. Acquired Immunodeficiency Syndrome · United States.
Among the 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States, this one is the 21st largest by enrollment of the 1,291 interventional ones that give a count, is one of 77 that started in 2019, is one of 642 with no phase, and was the 1,331st registered.
3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →112 of the 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States are open now. Recruiting first, the newest first:
Nicky Mehtani, MD, MPH · Sites in United States
Ages 25–64
Columbia University · Sites in United States
Ages 18+ · Healthy volunteers
BioNTech SE · Sites in United States, South Africa
Ages 18–50 · Healthy volunteers
CAN Community Health · Sites in United States
Ages 18+
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 34 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,671 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 385 · Phase 2 259 · Phase 3 156 · Phase 4 81
First in 1981; this study’s year is marked. 77 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,249 is above the median of 96 across 2,254 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Median enrollment 60 across the 1,291 interventional studies, 154 across the 195 observational. Of the 1,449 that completed or were terminated, 356 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
510 of 1,671 have an industry lead sponsor. The 10 most frequent:
Northwestern University is the lead sponsor of 1,424 studies on the registry; 199 are open to participants now.
Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.
Northwestern University has 7 studies filed under Acquired Immunodeficiency Syndrome — fewer than ten, so there is no comparison to draw.
55 of the studies in Acquired Immunodeficiency Syndrome with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04176172Phase 3Abramson Cancer Center at Penn MedicineOptimizing Tobacco Use Treatment for PLWHA | 2026-11-30 |
| NCT04958122Phase 3University of Southern CaliforniaCefixime Clinical Trial | 2027-01-01 |
| NCT07044297Phase 3Merck Sharp & Dohme LLCA Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) | 2027-07-22 |
| NCT04833829Emory UniversityCross-disciplinary HIV Integrated Mental Health Support Intervention | 2026-11 |
| NCT05159466Tulane UniversityTulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors | 2026-11 |
Add all 55 to your calendar (.ics) → With an account.
Among the 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates and compares two implementation strategies of an online HIV prevention intervention: Strategy 1 in which community-based organizations apply, and are selected, for funding to deliver Keep It Up! through current HIV testing programs; and Strategy 2 which is a "direct-to-consumer" model where centralized staff at Northwestern University recruit participants nationally through online advertising campaigns and manage engagement.
Substantial effort has gone into developing and testing the efficacy of eHealth HIV prevention interventions, but these interventions will not affect the spread of the epidemic unless implemented effectively to reach the most at-risk populations. Despite emerging evidence that eHealth approaches can be highly effective in reducing HIV risk or improving care engagement, implementation requirements do not fit within established strategies for public health scale up, leaving it an open question as to how to bring these programs into practice. To date, little to no implementation science has examined strategies to effectively scale up eHealth HIV prevention programs.
The overarching goal of this study is to address this need by developing and evaluating novel strategies for implementing eHealth HIV prevention programs. Keep It Up! (KIU!) is an online program proven to reduce HIV risk among diverse young men who have sex with men (YMSM). KIU! was designed for YMSM who just tested HIV negative to keep it up and maintain negative status by reducing risk and enacting protections. Strong evidence of effectiveness on behavioral (decreased condomless sex) and biomedical outcomes (reduced STI incidence) makes KIU! an ideal eHealth intervention for implementation research. Lessons learned from KIU! implementation will set the pathway for implementing the many HIV eHealth programs currently undergoing efficacy testing.
Implementation strategies need to be evaluated using rigorous research designs. Through formative research with community-based organizations (CBOs), health departments, the CDC, and researchers, the investigators have identified two pragmatic implementation strategies that will be evaluated and compared:
In Strategy 1, CBOs apply for, and are selected for, funding to deliver KIU! through current HIV testing programs. Because CBOs do not have the capacity to host the technology, KIU! is hosted centrally at Northwestern and deployed by local CBO staff. Training and coaching of CBO staff on how to use the technology and integrate it into routine HIV testing is provided through capacity building assistance.
Strategy 2 is a "direct-to-consumer" (DTC) model where centralized staff at Northwestern primarily recruit participants nationally through online advertising campaigns and manage participants' engagement. HIV/STI testing kits are shipped directly to YMSM, and upon documentation of an HIV negative test result, participants are delivered KIU! This DTC model has been widely adopted in technology dissemination but it is innovative in terms of implementation of HIV prevention programs.
The investigators will accomplish the goal to inform eHealth intervention implementation with two specific aims:
Aim 1: Compare two implementation strategies using a quasi-experimental trial.
The investigators selected a type III hybrid implementation-effectiveness design, which prioritizes empirical comparison of implementation strategies while also collecting evidence of effectiveness. KIU will be delivered using Strategy 1 (CBOs) in 22 counties for two years; simultaneously, the investigators will deliver KIU nationally using Strategy 2 (DTC). YMSM participants in the DTC strategy will be matched to CBO strategy participants based on post-hoc propensity scores. Implementation and effectiveness outcome data will be collected from YMSM participants, CBOs, and the technology vendor. The primary outcomes are public health impact (defined as reach X effectiveness) and cost per infection averted, a key component of CDC decision making about which HIV prevention programs will be supported. There continues to be equipoise for the trial (i.e., either strategy could be superior). Because implementation success can be defined differently for different stakeholders, the investigators will also continue to collect and report as secondary outcomes multiple metrics of reach, effectiveness, and implementation.
Aim 2: Examine adoption characteristics that explain variability in implementation outcomes.
There is remarkable variability in implementation success when CBOs adopt evidence-based interventions. The investigators will seek to explain variability in implementation success across counties by conducting mixed-methods research on the domains from the consolidated framework for implementation research (CFIR), such as county characteristics, adaptations, support from organization leadership, and approach to planning adoption. Data on CFIR characteristics will be collected through administrative data, surveys, and telephone interviews with key stakeholders.
In addition to these 2 specific aims, the investigators will explore sustainment of KIU! at the completion of the study. CBOs will be provided with materials to facilitate applying for external funding to continue to provide KIU! after study completion, including an Impact Tool to estimate local impact and costs. The investigators will also examine factors that predict applying for funding and ongoing sustainment. For Strategy 2, through consultation with the CDC, capacity building assistance providers, health departments, and small businesses involved in Health 2.0 initiatives, the investigators will examine models for ongoing sustainment of the DTC model.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CBOs will be selected through a Request for Proposal (RFP) process. The RFP will describe research and KIU! delivery activities to be conducted as part of the study and allowable budget to carry out the activities. The RFP will ask CBOs to describe past experience providing HIV services for YMSM. Selected CBOs will recruit participants into the intervention and encourage participants to complete each session of intervention content at baseline, 6 Week Follow-up, and 12 Week Follow-up. Participants in the CBO delivery arm will receive baseline HIV and STI testing at a CBO. Participants will receive an at-home STI test kit at 12 Week Follow-up if testing is not provided at their CBO site.
Behavioral: Keep It Up! 3.0
In the DTC arm, participants will be recruited online via paid social media advertising (e.g., Facebook, Instagram). Advertisements will target placements by age, gender, sexual orientation, racial background, "likes" that are relevant to YMSM (e.g., local LGBT organizations, "out" celebrities), and location (i.e., target county). Dating/sex-seeking apps (e.g., Grindr) will also be used to recruit YMSM, using a similar advertising approach as social media. These online recruitment strategies will be supplemented by referrals from local organizations and participant registries, and snowball recruitment. Study staff at Northwestern University will manage this recruitment process and encourage participants to complete each session of intervention content at baseline, 6 Week Follow-up, and 12 Week Follow-up. Participants in the DTC delivery arm will receive at-home HIV and STI test kits at baseline. Participants will receive an at-home STI test kit at 12 Week Follow-up.
Behavioral: Keep It Up! 3.0
KIU! is an online HIV prevention intervention developed for high-risk young men who have sex with men (YMSM) who recently tested HIV negative. Content was developed in collaboration with YMSM-serving CBOs and subjected to usability testing with diverse YMSM. The Information-Motivation-Behavioral Skills model and eLearning principles guided development of highly interactive, engaging, and culturally relevant health messages. KIU! involves 7 modules completed across 3 sessions, totaling \~1 hour of main content, plus 2 booster sessions at 6- and 12-week follow-ups. Each module is based on a setting or situation relevant to YMSM (e.g., connecting to the gay community and meeting guys through apps), with developmentally appropriate behavior change content embedded. KIU! uses diverse delivery methods (e.g. videos, animation, games) to address HIV knowledge gaps, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors.
Also known as: KIU! 3.0
Public Health Impact
Public Health Impact (PHI) is defined as the number of HIV infections averted. HIV infections averted were calculated as the difference between baseline and 12-week extrapolated HIV incidence rates (IRs) per 100 person-years. Given the incidence of HIV among YMSM in the US, very large sample sizes would be required to directly estimate HIV infections averted, so HIV IRs were extrapolated for each study arm-timepoint using a model predictive of HIV incidence published by Mulick and Murray (2020) that uses rectal gonorrhea infection as a determinant.
Time frame: 12 Weeks
Originally 66 counties with largest YMSM populations were randomized 2:1 into CBO \& DTC arms. 22 CBO counties selected from the 44 based on most competitive CBO applications. DTC arm revised to recruit nationally but could not recruit from CBO counties. No DTC participants assigned at local level, only nationally. Outcomes reported at participant level for more meaningful interpretations of study effects. Primary study outcome, public health impact, is wholly reliant on YMSM participant data.
| Milestone | Community Based Organization (CBO) Delivery | Direct to Consumer (DTC) Delivery |
|---|---|---|
| Started | 781 | 1468 |
| Community based organization (cbo) staff survey | 125 | 0 |
| Community based organization (cbo) ymsm participants | 656 | 0 |
| Completed | 354 | 1158 |
| Not completed | 427 | 310 |
Public Health Impact (PHI) is defined as the number of HIV infections averted. HIV infections averted were calculated as the difference between baseline and 12-week extrapolated HIV incidence rates (IRs) per 100 person-years. Given the incidence of HIV among YMSM in the US, very large sample sizes would be required to directly estimate HIV infections averted, so HIV IRs were extrapolated for each study arm-timepoint using a model predictive of HIV incidence published by Mulick and Murray (2020) that uses rectal gonorrhea infection as a determinant.
| HIV infections averted per 100 person-yr | Community Based Organization (CBO) Delivery | Direct to Consumer (DTC) Delivery |
|---|---|---|
| Public Health Impact | 1.65 (1.29 to 2.02) | 0.62 (0.49 to 0.74) |
Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Community Based Organization (CBO) Delivery | 0/656 (0%) | 0/656 (0%) | 0/656 (0%) |
| Direct to Consumer (DTC) Delivery | 0/1,468 (0%) | 0/1,468 (0%) | 0/1,468 (0%) |
| Community Based Organization (CBO) Staff | 0/125 (0%) | 0/125 (0%) | 0/125 (0%) |
| Age, Categorical(Participants) | Community Based Organization (CBO) Delivery | Direct to Consumer (DTC) Delivery | Community Based Organization (CBO) Staff | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 656 | 1468 | 125 | 2249 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Community Based Organization (CBO) Delivery | Direct to Consumer (DTC) Delivery | Community Based Organization (CBO) Staff | Total |
|---|---|---|---|---|
| Mean | 26.34 ± 4.08 | 26.04 ± 4.51 | 32.71 ± 9.33 | 26.13 ± 4.38 |
| Sex: Female, Male(Participants) | Community Based Organization (CBO) Delivery | Direct to Consumer (DTC) Delivery | Community Based Organization (CBO) Staff | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 35 | 35 |
| Male | 656 | 1468 | 90 | 2214 |
| Race (NIH/OMB)(Participants) | Community Based Organization (CBO) Delivery | Direct to Consumer (DTC) Delivery | Community Based Organization (CBO) Staff | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 11 | 40 | 4 | 55 |
| Asian | 50 | 166 | 4 | 220 |
| Native Hawaiian or Other Pacific Islander | 5 | 11 | 1 | 17 |
| Black or African American | 173 | 199 | 44 | 416 |
| White | 322 | 830 | 57 | 1209 |
| More than one race | 41 | 130 | 11 | 182 |
| Unknown or Not Reported | 54 | 92 | 4 | 150 |
| Ethnicity (NIH/OMB)(Participants) | Community Based Organization (CBO) Delivery | Direct to Consumer (DTC) Delivery | Community Based Organization (CBO) Staff | Total |
|---|---|---|---|---|
| Hispanic or Latino | 216 | 401 | 37 | 654 |
| Not Hispanic or Latino | 440 | 1067 | 88 | 1595 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Community Based Organization (CBO) Delivery | Direct to Consumer (DTC) Delivery | Community Based Organization (CBO) Staff | Total |
|---|---|---|---|---|
| United States | 656 | 1468 | 125 | 2249 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The PI agrees to develop a de-identified database, codebook, and mechanism by which IPD could be shared with other investigators upon approval of the PI. Data will be available for request approximately 6 months after completion of the project. Interested investigators will be asked to complete a standardized request form stating the specific aims of the analysis, the analytic plans, resources the requestors have to carry out the project, the proposed timeline, and distribution goals (manuscripts and/or grant application). The PI will review these requests to determine whether the proposed analyses constitute an innovative and significant exploration of the data, whether the proposed team has sufficient resources to undertake the request, how data will be protected/managed, and whether there are sufficient resources to honor the request. If any of these issues are problematic, the PI will attempt to negotiate a fair resolution with the interested parties and/or with NIH program staff.
Ran from Oct 2019 to primary completion in Mar 2023, 41 months.
Results were first posted in Oct 2026, 3 years 6 months after primary completion.
Of 642 non-industry interventional studies with no phase under Acquired Immunodeficiency Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's 41 months is above that.
Counting every sponsor, half of 648 studies reached it within 29 months; a quarter within 17 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acquired Immunodeficiency Syndrome →